# HLB Life Science Selected for Fifth National Minor Cannabinoid Project > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/minor-cannabinoid-drug-development-national-project/ > **Published:** 2026-07-06T07:37:43-04:00 | **Last Modified / Clinically Audited:** 2026-09-08T20:20:30-04:00 > **Clinical Summary:** HLB Life Science advances minor cannabinoid drug development in a fifth national project, highlighting new pharmaceutical research beyond THC and CBD. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. ResearchHempCBDTHCPolicyIndustrySafety Clinical Summary HLB Life Science has been selected for a fifth national research project focused on developing next-generation pharmaceuticals derived from [minor cannabinoids](https://cedclinic.com/cbd-vs-thc-vs-cbg-vs-cbn-vs-thcv-differences/), signaling increasing institutional investment in cannabinoid-based [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) beyond THC and CBD. This initiative reflects a broader scientific and regulatory shift toward understanding the therapeutic potential of lesser-studied cannabinoids such as CBG, CBN, and CBDA, which may offer novel mechanisms of action and improved safety profiles for various conditions. For clinicians, this development suggests that the pipeline of cannabis-derived medications will likely expand beyond current options, potentially offering more targeted therapeutic agents with characterized pharmacology and clinical efficacy data. As these compounds progress through formalized research and regulatory pathways, they could eventually transition from the current unregulated cannabis market to standardized pharmaceutical products with defined dosing, purity, and clinical indications. Clinicians should monitor emerging literature on [minor cannabinoids](https://cedclinic.com/cbd-vs-thc-vs-cbg-vs-cbn-vs-thcv-differences/) to stay informed about future treatment options and understand the distinction between speculative cannabis products and evidence-based cannabinoid pharmaceuticals when counseling patients. Dr. Caplan’s Take “What’s encouraging here is that we’re seeing sustained institutional investment in minor [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/), but I want to be clear: we’re still in the early signal phase with most of these compounds, and the jump from promising bench work to clinically meaningful pharmaceuticals is long and uncertain. We need rigorous human trials before we can responsibly incorporate these into practice.” Clinical Perspective 🔬 While industry investment in minor [cannabinoid research](https://cedclinic.com/cannabinoids-in-reward-processing-pain-perception/) reflects growing commercial interest in cannabis-derived therapeutics, clinicians should recognize that most [minor cannabinoids](https://cedclinic.com/cbd-vs-thc-vs-cbg-vs-cbn-vs-thcv-differences/) (cannabinol, cannabigerol, tetrahydrocannabivarin, and others) remain poorly characterized in human studies compared to THC and CBD. The transition from laboratory development to clinical evidence takes years, and current enthusiasm in the industry may outpace the actual establishment of safety and efficacy data needed for informed prescribing. Additionally, regulatory pathways for cannabinoid pharmaceuticals continue to evolve, and products developed through private R&D may face variable approval timelines and clinical trial rigor depending on jurisdiction. Until robust clinical data emerges from well-designed trials, providers should maintain appropriate skepticism toward marketed minor cannabinoid products and educate patients that “research-backed” development announcements do not yet constitute clinical evidence. A practical approach is to distinguish between promising prec 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20HLB%20Life%20Science%20R%26amp%3BD%20Selected%20for%20Fifth%20National%20Project%20This%20Year...%20Launches%20Next%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68368)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68368)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20HLB%20Life%20Science%20R%26amp%3BD%20Selected%20for%20Fifth%20National%20Project%20This%20Year...%20Launches%20Next%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D68368)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) 📰 Source: [https://www.asiae.co.kr/en/article/stock-disclosure/2026070608062519388](https://www.asiae.co.kr/en/article/stock-disclosure/2026070608062519388) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [HLB Life Science R&D Launches Minor Cannabinoid Drug Development in Fifth State Project](https://cedclinic.com/hlb-life-science-rd-launches-minor-cannabinoid-drug-development-in-fifth-state-project/) Explore how HLB Life Science is pioneering minor cannabinoid [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/) through its latest state-level research initiative. [Read More](https://cedclinic.com/hlb-life-science-rd-launches-minor-cannabinoid-drug-development-in-fifth-state-project/) [Why Pharma Is Taking Cannabis Seriously – The Dales Report](https://cedclinic.com/why-pharma-is-taking-cannabis-seriously-the-dales-report/) Understand the pharmaceutical industry’s growing interest in cannabis and its implications for [drug development](https://cedclinic.com/hydrogen-sulfide-releasing-nsaid-derivative/). [Learn More](https://cedclinic.com/why-pharma-is-taking-cannabis-seriously-the-dales-report/) [Federal Marijuana Reclassification Could Reshape Medical Research and Cannabis Industry](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) Discover how federal marijuana reclassification may impact [medical research](https://cedclinic.com/cb2-receptor-agonist-parkinsons/) and the future of cannabinoid pharmaceuticals. [Explore Insights](https://cedclinic.com/federal-marijuana-rescheduling-medical-research-clinical-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).